Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT.
(2020) Leukemia and Lymphoma — Vol. 61, n° 12, p. 2915-2922 (2020)
Files
2020_Martinez_Leuk_Lymphoma.pdf
Postprint
Open Access - Adobe PDF
- 2.29 MB
Details
- Authors
- Abstract
- The purpose of this study was to analyze the results of second autologous hematopoietic stem cell transplantation (ASCT2) for patients with relapsed/refractory Hodgkin lymphoma (HL) after a first transplantation (ASCT1). Outcomes for 56 patients receiving an ASCT2 registered in the EBMT database were analyzed. The 4-year cumulative incidences of non-relapse mortality and disease relapse/progression were 5% and 67%, respectively. The 4-year overall survival (OS) and progression-free survival (PFS) were 62% and 28%. In univariate analysis, relapse of HL within 12 months of ASCT1 was associated with a worse OS (35% versus 76%, = 0.01) and PFS (19% versus 29%, = 0.059). Chemosensitivity at ASCT2 predicted better outcomes (4-year OS 72% versus 29%, = 0.002; PFS 31% versus 12%, = 0.015). This series shows that ASCT2 is a safe procedure and a relatively effective option for patients with late relapses after ASCT1 and with chemosensitive disease who are not eligible for an allogeneic transplant.
- Affiliations
Citations
Martínez, C., Boumendil, A., Romejko-Jarosinska, J., Anagnostopoulos, A., Faber, E., Poire, X., Yakoub-Agha, I., Akhtar, S., Gurman, G., Pavone, V., Halaburda, K., Sousa, A. B., Ghesquières, H., Finel, H., Khvedelidze, I., Montoto, S., & Sureda, A. (2020). Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT. Leukemia and Lymphoma, 61(12), 2915-2922. https://doi.org/10.1080/10428194.2020.1789624 (Original work published 2020)